An Open-label, Multicenter, Phase I Dose-escalation Trial of EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and Acquired EGFR p.T790M-positive Resistance to 1st or 2nd Generation EGFR TKI Therapy Remark: According to Version V02_0 of the Protocol, Patients May Also be Eligible if EGFR TKI-treatment naïve, EGFR p.T790M-negative at Progression While on EGFR TKI Therapy or After Progression While on Osimertinib Treatment
Overview
- Phase
- Phase 1
- Intervention
- EGF816
- Conditions
- Bronchial Neoplasms
- Sponsor
- University of Cologne
- Enrollment
- 18
- Locations
- 7
- Primary Endpoint
- Incidence of dose-limiting-toxicities (DLT) of the combination of EGF816 and trametinib to assess the maximum tolerated dose (MTD)/recommended phase II dose (RP2D)
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The aim of this trial is to identify the maximum tolerated dose (MTD)/recommended phase II dose (RP2D), to define pharmacokinetic (PK) parameters and the preliminary efficacy of a continuous treatment with EGF816 and trametinib in locally advanced or metastatic (stage IIIB or IV) lung cancer patients with activating mutations in the epithelial growth factor receptor (EGFR).
Detailed Description
The population of interest for this trial is defined by patients with non-small cell lung cancer (NSCLC) harbouring the sensitizing EGFR mutations del19 or p.L858R. Patients may be enrolled in first- or later lines of therapy and independently of the prior (approved) EGFR inhibitor administered and independently of the EGFR p.T790M-status. Those individuals whose tumors harbour high-level amplifications of MET or other EGFR mutations except for del19, p.L858R or p.T790M will be excluded from the trial. The molecular status must have been determined in a biopsy collected at progression to the last systemic and prior to the initiation of the trial treatment The aim of the trial is to identify the maximum tolerated dose (MTD)/recommended phase II dose (RP2D) for a continuous treatment with the 3rd generation EGFR inhibitor EGF816 and the MEK inhibitor trametinib. The recommendations for dose level escalations will be based on an "up-and-down" design proposed by Storer, 1989. The dose limiting toxicity (DLT) period comprises the first 28 days of treatment with EGF816 and trametinib at the designated dose level (Cycle 1). PK parameters of the combination treatment will be assessed for every dose level in every patient during the dose-escalation part. Preliminary efficacy of EGF816 and trametinib in the trial population will be assessed by RECIST (v1.1) analysis of scheduled CT scans (every 8 weeks or as clinically indicated. Throughout the study blood samples will be collected to monitor cell free plasma DNA (cfDNA). Patients who develop resistance upon treatment with the study drugs will undergo a rebiopsy to identify potential mechanisms of resistance.
Investigators
Prof. Dr. Juergen Wolf
Prof. Dr.
University of Cologne
Eligibility Criteria
Inclusion Criteria
- •Written informed consent must have been obtained prior to any screening procedures.
- •Patients (male or female) ≥ 18 years of age.
- •Histologically documented, locally advanced or recurrent (stage IIIB who are not eligible for combined modality treatment) or metastatic (stage IV) non-small cell lung cancer.
- •Presence of at least one measurable lesion according to RECIST v.1.
- •ECOG performance status ≤ 2
- •Patients must have NSCLC harbouring EGFR p.L858R or EGFR del19 as assessed by local testing.
- •Patients must be EGFR TKI treatment naïve (prior chemotherapy treatment is allowed) or must have progressed while on continuous treatment with a first- or second-generation EGFR TKI (EGFR p.T790M-negative or -positive) or must have progressed while on continuous treatment with osimertinib (EGFR p.T790M-negative or -positive)
- •In patients who have received no prior EGFR TKI treatment, an archival biopsy sample, defined as a sample being obtained prior to any anti-cancer treatment is mandatory. If an archival biopsy fulfilling this criterion is not available, patients must be suitable and willing to undergo baseline biopsy according to the local institution's guidelines (newly obtained biopsy).
- •In patients who have received prior EGFR TKI treatment, an archival biopsy sample, defined as a sample being obtained after or during progression upon the last anti-cancer treatment is mandatory. No consecutive line of treatment must have been given after collection of the rebiopsy and inclusion into this trial. If an archival rebiopsy fulfilling these criteria is not available, patients must be suitable and willing to undergo baseline biopsy according to the local institution's guidelines (newly obtained biopsy).
- •In patients who have received prior EGFR TKI treatment, EGFRp.T790M mutation status must have been assessed by local testing in the tumour sample fulfilling the requirements of inclusion criterion
Exclusion Criteria
- •History of allergic reactions or hypersensitivity to one of the study drugs or to any component of the study drugs
- •Prior treatment with any investigational agent known to inhibit EGFR (mutant or wild-type)
- •Prior treatment with any agent known to inhibit MEK/ERK or other mediators of RAS pathway.
- •Patients with high level MET amplification in the archival or newly obtained biopsy sample as determined by local testing. High-level MET amplification is defined as: a) a MET/CEN7 ratio ≥2.0 and/or b) an average MET gene copy number per cell of ≥6.0 \[modified Schildhaus et al., 2015\].
- •Patients with EGFR mutations other than EGFR del19, p.L858R or p.T790M.
- •Patients with brain metastases. However, if radiation therapy and/or surgery has been completed at least 4 weeks prior to screening for the trial and evaluation by CT (with contrast enhancement) or MRI at study baseline demonstrates the disease to be stable and if the patient remains asymptomatic and off steroids, then patients with brain metastases may be enrolled.
- •Patients with presence or history of carcinomatous meningitis.
- •Any acute or chronic medical, mental or psychological condition, which in the opinion of the investigator would not permit the patient to participate or complete the study or understand the patient information
- •History of hepatitis B (HBV) or hepatitis C (HCV) or positive result in mandatory testing for acute or chronic hepatitis B or hepatitis C
- •Known HIV infection or history of HIV infection independent from the cellular immune status
Arms & Interventions
EGF816 (nazartinib) and trametinib
Patients will receive oral EGF816 (nazartinib) and trametinib at escalating dose levels. Intra-patient dose-escalation will not be allowed.
Intervention: EGF816
EGF816 (nazartinib) and trametinib
Patients will receive oral EGF816 (nazartinib) and trametinib at escalating dose levels. Intra-patient dose-escalation will not be allowed.
Intervention: Trametinib
Outcomes
Primary Outcomes
Incidence of dose-limiting-toxicities (DLT) of the combination of EGF816 and trametinib to assess the maximum tolerated dose (MTD)/recommended phase II dose (RP2D)
Time Frame: Approximately one and a half years (from FPFV until the end of the DLT period of the last patient included into the trial or until death of the last patient, whichever occurs first)
Incidence of dose-limiting-toxicities (DLT) that occur during the DLT period (i.e. first 4 weeks of treatment) of each patient in the dose-escalation part (N=18)
Secondary Outcomes
- Progression-free survival (PFS) according to RECIST 1.1(Approximately 4 years (from FPFV until the progression of the last patient treated within the trial or until death of the last patient, whichever occurs first))
- Duration of response (DOR) according to RECIST 1.1(Approximately 4 years (from FPFV until the progression of the last patient treated within the trial or until death of the last patient, whichever occurs first))
- Disease control rate (DCR) according to RECIST 1.1(Approximately 4 years (from FPFV until the progression of the last patient treated within the trial or until death of the last patient, whichever occurs first))
- overall survival (OS)(Approximately 4 years (from FPFV until the progression of the last patient treated within the trial or until death of the last patient, whichever occurs first))
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.03(Approximately four years (from FPFV until the completion of the clinical trial))
- Number of patients who experienced dose interruptions or reductions(Approximately four years (from FPFV until the end-of-treatment visit of the last patient or until death of the last patient, whichever occurs first))
- Time to response (TTR) according to RECIST 1.1(Approximately 4 years (from FPFV until the progression of the last patient treated within the trial or until death of the last patient, whichever occurs first))
- Objective response rate (ORR) according to RECIST 1.1(Approximately 4 years (from FPFV until the progression of the last patient treated within the trial or until death of the last patient, whichever occurs first))
- Plasma concentration vs time profiles - plasma PK parameters of EGF816 and trametinib(Approximately two years (from FPFV until the completion of four months of treatment of the last patient or until death of the last patient, whichever occurs first))